PMID- 35011882
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220114
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 11
IP  - 1
DP  - 2021 Dec 27
TI  - Effects of SGLT2 Inhibitors on Atherosclerosis: Lessons from Cardiovascular 
      Clinical Outcomes in Type 2 Diabetic Patients and Basic Researches.
LID - 10.3390/jcm11010137 [doi]
LID - 137
AB  - Atherosclerosis-caused cardiovascular diseases (CVD) are the leading cause of 
      mortality in type 2 diabetes mellitus (T2DM). Sodium-glucose cotransporter 2 
      (SGLT2) inhibitors are effective oral drugs for the treatment of T2DM patients. 
      Multiple pre-clinical and clinical studies have indicated that SGLT2 inhibitors 
      not only reduce blood glucose but also confer benefits with regard to body 
      weight, insulin resistance, lipid profiles and blood pressure. Recently, some 
      cardiovascular outcome trials have demonstrated the safety and cardiovascular 
      benefits of SGLT2 inhibitors beyond glycemic control. The SGLT2 inhibitors 
      empagliflozin, canagliflozin, dapagliflozin and ertugliflozin reduce the rates of 
      major adverse cardiovascular events and of hospitalization for heart failure in 
      T2DM patients regardless of CVD. The potential mechanisms of SGLT2 inhibitors on 
      cardioprotection may be involved in improving the function of vascular 
      endothelial cells, suppressing oxidative stress, inhibiting inflammation and 
      regulating autophagy, which further protect from the progression of 
      atherosclerosis. Here, we summarized the pre-clinical and clinical evidence of 
      SGLT2 inhibitors on cardioprotection and discussed the potential molecular 
      mechanisms of SGLT2 inhibitors in preventing the pathogenesis of atherosclerosis 
      and CVD.
FAU - Xu, Jing
AU  - Xu J
AD  - Department of Diabetology and Endocrinology, Kanazawa Medical University, 
      Uchinada, Ishikawa 920-0293, Japan.
FAU - Hirai, Taro
AU  - Hirai T
AUID- ORCID: 0000-0002-7278-3417
AD  - Department of Diabetology and Endocrinology, Kanazawa Medical University, 
      Uchinada, Ishikawa 920-0293, Japan.
FAU - Koya, Daisuke
AU  - Koya D
AUID- ORCID: 0000-0003-2711-1539
AD  - Department of Diabetology and Endocrinology, Kanazawa Medical University, 
      Uchinada, Ishikawa 920-0293, Japan.
AD  - Division of Anticipatory Molecular Food Science and Technology, Medical Research 
      Institute, Kanazawa Medical University, Uchinada, Ishikawa 920-0293, Japan.
AD  - Omi Medical Center, Omi General Hospital, Kusatsu, Shiga 525-8585, Japan.
FAU - Kitada, Munehiro
AU  - Kitada M
AUID- ORCID: 0000-0002-3854-1385
AD  - Department of Diabetology and Endocrinology, Kanazawa Medical University, 
      Uchinada, Ishikawa 920-0293, Japan.
AD  - Division of Anticipatory Molecular Food Science and Technology, Medical Research 
      Institute, Kanazawa Medical University, Uchinada, Ishikawa 920-0293, Japan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20211227
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC8745121
OTO - NOTNLM
OT  - SGLT2 inhibitors
OT  - atherosclerosis
OT  - cardiovascular disease
OT  - diabetes
COIS- The authors declare that they have no conflict of interest.
EDAT- 2022/01/12 06:00
MHDA- 2022/01/12 06:01
PMCR- 2021/12/27
CRDT- 2022/01/11 01:16
PHST- 2021/12/01 00:00 [received]
PHST- 2021/12/21 00:00 [revised]
PHST- 2021/12/24 00:00 [accepted]
PHST- 2022/01/11 01:16 [entrez]
PHST- 2022/01/12 06:00 [pubmed]
PHST- 2022/01/12 06:01 [medline]
PHST- 2021/12/27 00:00 [pmc-release]
AID - jcm11010137 [pii]
AID - jcm-11-00137 [pii]
AID - 10.3390/jcm11010137 [doi]
PST - epublish
SO  - J Clin Med. 2021 Dec 27;11(1):137. doi: 10.3390/jcm11010137.